Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon alpha-2a and ribavirin: a multicentric study.

Puoti C, Pellicelli AM, Romano M, Mecenate F, Guarisco R, Barbarini G, Mazzoni E, Spilabotti L, Bellis L, Paglia F, Barlattani A, Picardi A, Paffetti A, Bonaventura ME, Nosotti L, Mitidieri O, Dell'Unto O, Villani R, Dell'Unto C, Morrone A, Soccorsi F; Club Epatologico Ospedaliero (Hospital Liver Club - CLEO).

Liver Int. 2009 Nov;29(10):1479-84. doi: 10.1111/j.1478-3231.2009.02042.x. Epub 2009 Apr 28.

PMID:
19422478
2.

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.

Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P; Austrian Hepatitis Study Group.

Gastroenterology. 2008 Aug;135(2):451-8. doi: 10.1053/j.gastro.2008.04.015. Epub 2008 May 27.

PMID:
18503773
3.

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, Hsu CS, Tseng TC, Wang CC, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH.

Clin Infect Dis. 2008 Nov 15;47(10):1260-9. doi: 10.1086/592579.

4.

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.

Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, Shiffman M, Farci P, Gitlin N, O'Brien CB, Lamour F, Lardelli P; PEGASYS Study NR16071 Investigator Group.

Gastroenterology. 2004 Dec;127(6):1724-32.

PMID:
15578510
6.

Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus.

Yu JW, Sun LJ, Zhao YH, Kang P, Gao J, Li SC.

Liver Int. 2009 Nov;29(10):1485-93. doi: 10.1111/j.1478-3231.2009.02080.x. Epub 2009 Jul 7.

PMID:
19602134
7.

Rapid virological response as a predictor of sustained response in HCV-infected patients with persistently normal alanine aminotransferase levels: A multicenter study.

Puoti C, Barbarini G, Picardi A, Romano M, Pellicelli A, Barlattani A, Mecenate F, Guarisco R, Costanza OM, Spilabotti L, Bellis L, Bonaventura ME, Dell' Unto O, Elmo MG, Nicolini AM, Nosotti L, Soccorsi F; Club Epatologico Ospedaliero (Hospital Liver Club, CLEO).

J Viral Hepat. 2011 Jun;18(6):393-9. doi: 10.1111/j.1365-2893.2010.01319.x.

PMID:
20546499
8.

Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.

Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F; SMIEC II Investigators.

Eur J Gastroenterol Hepatol. 2008 Jul;20(7):680-7. doi: 10.1097/MEG.0b013e3282f5196c.

PMID:
18679072
9.

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.

Lawitz E, Rodriguez-Torres M, Muir AJ, Kieffer TL, McNair L, Khunvichai A, McHutchison JG.

J Hepatol. 2008 Aug;49(2):163-9. doi: 10.1016/j.jhep.2008.03.027. Epub 2008 Apr 29.

PMID:
18486984
10.

Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin.

Weiland O, Hollander A, Mattsson L, Glaumann H, Lindahl K, Schvarcz R, Lindh G, Enquist R, Quist A.

J Viral Hepat. 2008 Sep;15(9):641-5. doi: 10.1111/j.1365-2893.2008.00999.x. Epub 2008 May 27.

PMID:
18507753
11.

Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin.

Snoeck E, Hadziyannis SJ, Puoti C, Swain MG, Berg T, Marcellin P, Zarski JP, Jorga K, Zeuzem S.

Liver Int. 2008 Jan;28(1):61-71. Epub 2007 Oct 25.

PMID:
17971091
12.

Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.

Tural C, Galeras JA, Planas R, Coll S, Sirera G, Giménez D, Salas A, Rey-Joly C, Cirera I, Márquez C, Tor J, Videla S, García-Retortillo M, Clotet B, Solà R.

Antivir Ther. 2008;13(8):1047-55.

PMID:
19195330
13.

Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients.

Reddy KR, Messinger D, Popescu M, Hadziyannis SJ.

J Viral Hepat. 2009 Oct;16(10):724-31. doi: 10.1111/j.1365-2893.2009.01122.x.

PMID:
19486469
14.

Re-treatment of patients with hepatitis C who failed to respond (nonresponders) to previous treatment.

Sharvadze LG, Gogichaishvili ShSh, Sakandelidze TsG, Zhamutashvili MT, Chkhartishvili NI.

Georgian Med News. 2009 Jan;(166):61-4.

PMID:
19202222
15.

Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.

Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB.

Gastroenterology. 2009 Mar;136(3):856-62. doi: 10.1053/j.gastro.2008.11.037. Epub 2008 Nov 19.

PMID:
19135998
16.

Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.

Parise E, Cheinquer H, Crespo D, Meirelles A, Martinelli A, Sette H, Gallizi J, Silva R, Lacet C, Correa E, Cotrim H, Fonseca J, Paraná R, Spinelli V, Amorim W, Tatsch F, Pessoa M; Brazilian Pegasys Cooperative Study Group.

Braz J Infect Dis. 2006 Feb;10(1):11-6. Epub 2006 Jun 2.

17.

Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.

Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW.

Gastroenterology. 2002 Oct;123(4):1070-83.

PMID:
12360469
18.

Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life.

Arora S, O'Brien C, Zeuzem S, Shiffman ML, Diago M, Tran A, Pockros PJ, Reindollar RW, Gane E, Patel K, Wintfeld N, Green J.

J Gastroenterol Hepatol. 2006 Feb;21(2):406-12.

PMID:
16509866
19.

[Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].

Husa P, Slesinger P, Stroblová H, Svobodník A, Husová L.

Klin Mikrobiol Infekc Lek. 2008 Apr;14(2):67-73. Czech.

PMID:
18756436
20.
Items per page

Supplemental Content

Write to the Help Desk